Novo Integrated Science and Clinical Consultants International a Novo wholly-owned subsidiary, announced the signing of a Consulting Services Agreement, with Futura Surgicare Pvt Ltd, an India-based leading manufacturer of wound closure and surgical products that are marketed and distributed in over 70 countries worldwide under the trade name “Dolphin Sutures”. Futura’s comprehensive and innovative product offering includes surgical sutures, skin staplers, hernia meshes, surgical tapes, hemostats, and bone wax. The Agreement provides for (i) CCI to assist Futura in obtaining U.S. FDA 510K approvals for its advanced surgical products, and (ii) CCI and Futura to enter into a strategic partnership to introduce high-quality Dolphin Sutures and mesh products to the North American healthcare market, potentially bringing substantial cost savings and improved care to American patients and healthcare providers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVOS:
- Novo Integrated Sciences Announces Global Partnership with Futura Surgicare
- Novo Integrated Sciences Negotiates Waiver on Promissory Note
- Novo Integrated Sciences Announces Executive Leadership Changes
- Novo Integrated Sciences appoints Robert Oliva as new President
- Novo Integrated Sciences Warned by Nasdaq over Share Price